Vazyme(688105) Orient Securities·2025-01-22 14:21Investment Rating - The report maintains a "Buy" rating for the company with a target price of 27.98 CNY [3][6]. Core Views - The company is experiencing rapid growth in overseas business and is optimistic about the volume of new products being launched [2]. - Revenue and profit forecasts have been adjusted downwards due to industry demand fluctuations, reduced income from COVID-19 products, and increased R&D investments [3]. - The company is expected to achieve earnings per share of -0.03 CNY in 2024, 0.27 CNY in 2025, and 0.45 CNY in 2026 [3]. Financial Performance Summary - The company's revenue for 2022 was 3,569 million CNY, with a projected decline to 1,286 million CNY in 2023, followed by a recovery to 1,467 million CNY in 2024, and further growth to 1,845 million CNY in 2025 and 2,287 million CNY in 2026 [5]. - The gross profit margin is expected to improve from 71.0% in 2023 to 77.3% by 2026 [5]. - The net profit attributable to the parent company is projected to recover from a loss of 71 million CNY in 2023 to a profit of 179 million CNY in 2026 [5]. Business Segment Insights - The life sciences segment is seeing stable growth with continuous upgrades and new product launches [7]. - The in vitro diagnostics segment has expanded its reach, covering over 2,800 hospitals with rapid growth in respiratory pathogen detection products [7]. - The biopharmaceutical segment has achieved significant production scale, becoming a major supplier of enzyme raw materials in China [7]. R&D and Cost Management - The company has maintained a strong commitment to R&D, with R&D expenses accounting for 21.8% of revenue in the first three quarters of 2024 [7]. - Effective cost control measures have led to a reduction in management and sales expense ratios [7].